Net income for 2025 was reported at $457,417, a substantial turnaround from a net loss of $259,239 in 2024. This improvement was supported by a significant reduction in interest expenses, which fell to $237,413 from $465,055, following the restructuring and extinguishment of nearly all funded debt. Additionally, the company recorded a gain of approximately $1.15 million related to the extinguishment of convertible debt, further strengthening its balance sheet.
QHSLab's operational momentum is evident as it continues to diversify its revenue streams across diagnostics, therapeutics, and digital health services. The company is well-positioned for growth in 2026, focusing on expanding its physician network and scaling its digital health infrastructure. CEO Troy Grogan emphasized the importance of the ISP as a long-term growth driver, stating, "2025 marked an important year of operational progress and financial strengthening for QHSLab. We believe the Company is well positioned to continue building long-term shareholder value." With improving operating fundamentals and a stronger balance sheet, QHSLab is set to capitalize on its growth potential in the coming year.